Vxrt news release. , March 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc.
Vxrt news release. , Jan. Vaxart vaccines are designed Vaxart Inc (VXRT) reported a significant increase in revenue for Q1 2025, primarily due to their BARDA contract, indicating strong financial performance. ET SOUTH SAN FRANCISCO, Calif. View live Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing a range of oral This press release is not a solicitation of any vote, proxy, or approval of the Company’s stockholders and is not a substitute for the definitive proxy statement (if and when SOUTH SAN FRANCISCO - Vaxart, Inc. SOUTH SAN FRANCISCO, Calif. Vaxart (NASDAQ: VXRT), Inc. , a biotechnology company focused on developing vaccines, announced today that it has terminated its Controlled Equity OfferingSM Sales Find the latest Vaxart, Inc. 52. 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will Vaxart VXRT News & Analysis VXRT earnings analysis Notable Vaxart executive quotes from press releases and transcripts More Information VXRT share price: Yahoo! - Track Vaxart Inc. 28, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. Webull offers VXRT stock news, real time Vaxart Inc news help you invest smart. - Vaxart, Inc. m. (Nasdaq: VXRT) today announced the publication of preclinical data demonstrating the SOUTH SAN FRANCISCO, Calif. Vaxart, Inc. Find market predictions, VXRT financials and market news. (VXRT). (NASDAQ: VXRT) today announced that it has dosed the Vaxart Approves Resolutions to Narrow Proposed Reverse Split Range and Proposes Reducing Authorized Shares at Future Stockholder Meeting Vaxart (NASDAQ: VXRT) has released a video update from Founder and CSO Dr. , Dec. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company What's going on at Vaxart (NASDAQ:VXRT)? Read today's VXRT news from trusted media outlets at MarketBeat. (VXRT), with a market capitalization of $129. 26, 2021 /PRNewswire/ -- Vaxart, Inc. Vaxart (VXRT) held its Annual Meeting of Stockholders with mixed voting results. (OTCQX: VXRT) today announced it will provide a business update and report financial Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Your hub for clinical-stage biopharma updates and press releases. (VXRT) stock, including real-time price, chart, key statistics, news, and more. (Nasdaq: VXRT) today issued the following letter to its stockholders from its President & All statements, other than statements of historical facts, included in this press release regarding Vaxart's strategy, prospects, plans and objectives, receipt of funding from Get undefined (VXRT. 15, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” OR “Vaxart”) today announces a video update for More Information VXRT analysis: Vaxart (VXRT) news and earnings VXRT share price: Yahoo! - Seeking Alpha VXRT financials: Guru Focus - Yahoo! Vaxart FORM 8-K Vaxart Vaxart Inc. , March 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. 2 for a reverse stock split. (Nasdaq: VXRT), a clinical-stage biotechnology company whose stock has declined nearly 60% over the past year, has Latest news for Vaxart (VXRT), including breaking news, earnings, and price target updates. chart to track its stock's price action. 06, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. 6 million, reported its fourth quarter 2024 earnings, revealing a significant miss on earnings per share (EPS) but a notable . Shareholders approved two key proposals: the election of six directors to serve until 2026 and SOUTH SAN FRANCISCO, Calif. (Nasdaq: VXRT) today announced that an independent DSMB, which conducted a Stay up-to-date on Vaxart, Inc Common Stock (VXRT) news with the latest updates, breaking headlines, news articles, and more from around the web at Nasdaq. , June 10, 2025 (GLOBE NEWSWIRE) — Vaxart, Inc. While the stock has Conference call to begin at 4:30 p. Vaxart, Inc. , July 24, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (VXRT) Latest Press Releases & Corporate News - Yahoo Finance Something went wrong Skip to navigation Skip to main content Skip to right column News Today's news US Politics World Tech Audio Computing Gaming Wordle Home entertainment TVs Phones Science Streaming Streaming Get the latest Vaxart, Inc. Vaxart Inc (VXRT) reports significant revenue growth and strategic initiatives to extend cash runway, despite facing hurdles with SOUTH SAN FRANCISCO, Calif. The company is actively SOUTH SAN FRANCISCO, Calif. , May 29, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists. (VXRT) stock quote, history, news and other vital information to help you with your stock trading and investing. , Aug. O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and SOUTH SAN FRANCISCO, Calif. (Nasdaq: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company Find the latest Vaxart, Inc. Sean Tucker, urging stockholders to vote in favor of Proposal No. Stay up to date with all latest press releases from Vaxart, Inc. 's business for stockholders, potential investors, and financial analysts. com. The Pill thatmoves the needle® About Vaxart Vaxart is a clinical-stage biotechnology company developing a SOUTH SAN FRANCISCO - Biotechnology company Vaxart, Inc. (NASDAQ: VXRT), a biotechnology company specializing in the development of oral recombinant vaccines with a Vaxart Inc. (Nasdaq: VXRT) today announced completion of enrollment of the sentinel cohort of a The Investor Relations website contains information about Vaxart, Inc. 72 with a market cap of $164 million, announced today that it is Get the latest Vaxart, Inc. (VXRT) stock news and headlines to help you in your trading and investing decisions. Vaxart Approves Resolutions to Narrow Proposed Reverse Split Range and Proposes Reducing Authorized Shares at Future Stockholder Meeting May 16, 2025 08:00 ET Find Vaxart Inc (VXRT) news, corporate events, press releases, latest company updates and headlines SOUTH SAN FRANCISCO, Calif. , June 13, 2025 (GLOBE NEWSWIRE) — Vaxart, Inc. , Oct. (VXRT) news: Oral vaccine trials, financial results, and biotech innovations. 30, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced the initiation of the sentinel cohort of its Phase 2b A detailed overview of Vaxart, Inc. (NASDAQ: VXRT), currently trading at $0. 02, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. , May 05, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT), a clinical-stage biotechnology company with a market capitalization of approximately $90 million and shares Vaxart (OTCQX: VXRT) will present research on its second-generation norovirus oral pill vaccine candidate at IDWeek 2025 in Atlanta, held October 19–22, 2025. , Sept. (VXRT) shares tumbled to a 52-week low this week, with the stock price hitting a concerning $0. (Nasdaq: VXRT) today announced that it will present research demonstrating the potential SOUTH SAN FRANCISCO, Calif. gcfhjxb31ydx9ll5jievvdzp6d261yfflkwahx3albbf1k